FIELD: biochemistry.
SUBSTANCE: described is nucleic acid molecule for gene therapy of mucopolysaccharidoses. Also described are vectors and pharmaceutical compositions for treating mucopolysaccharidosis disease.
EFFECT: invention widens range of agents for treating mucopolysaccharidoses.
15 cl, 15 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IV A | 2019 |
|
RU2794960C2 |
| ADENO-ASSOCIATED VIRUS VECTORS FOR TREATING LYSOSOMAL STORAGE DISEASES | 2015 |
|
RU2718248C2 |
| VECTORS BASED ON ADENO-ASSOCIATED VIRUSES FOR TREATING MUCOPOLYSACCHARIDOSES | 2016 |
|
RU2744593C2 |
| CODON-OPTIMISED HAIPL1-ENCODING NUCLEOTIDE SEQUENCE AND EXPRESSION VECTOR CONTAINING SAID SEQUENCE | 2021 |
|
RU2785621C1 |
| ADENO-ASSOCIATED VIRUS VECTOR | 2015 |
|
RU2743382C2 |
| COMPOSITIONS AND METHODS OF TREATING MPS1 | 2014 |
|
RU2708318C2 |
| RNAi AGENT OPTION | 2018 |
|
RU2789647C2 |
| TREATMENT OF DISEASES BY MEANS OF EXPRESSION OF ENZYME WITH DEOXYRIBONUCLEASE (DNase) ACTIVITY IN LIVER | 2019 |
|
RU2773691C2 |
| VECTOR | 2017 |
|
RU2749479C1 |
| VECTORS FOR TREATMENT OF FRIEDREICH'S ATAXIA | 2018 |
|
RU2774892C2 |
